Hemolytic anemia classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(14 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hemolytic anemia}}
{{Hemolytic anemia}}
{{CMG}}
{{CMG}}; {{shyam}}


==Overview==
==Overview==
Hemolytic anemia can be divided into intravascular and extravascular based on whether the destruction of RBC occurs in the vessels or outside the vessels usually in spleen and liver. Extravascular hemolytic anemia are commoner than intravascular. There are many types of [[hemolytic anemia]]s and the general classification of hemolytic anemia is either acquired or inherited.
Hemolytic anemia can be divided into [[intravascular]] and extravascular based on whether the [[Hemolysis|destruction of RBCs]] occurs in the [[vessels]] or outside the vessels, usually in [[spleen]] and [[liver]]. Extravascular hemolytic anemia is more common than intravascular hemolytic anemia. There are many types of [[hemolytic anemia]]s and the general classification of hemolytic anemia is either acquired or [[inherited]] (genetic). [[Genetic]] conditions include [[red blood cell]] membrane or [[enzyme]] defects that predispose the [[red blood cells]] to [[hemolysis]].
 
==Classification==
==Classification==
===Location of Hemolysis===
*'''Intravascular''': This refers to [[Hemolysis|red blood cell destruction]] within [[Blood vessels|the blood vessels]].
*'''Extravascular''': This refers to [[Hemolysis|red blood cell destruction]] outside the blood vessels, such as in the [[liver]] or [[spleen]].
===Types of Hemolytic Anemias===
===Types of Hemolytic Anemias===
*[[Immune hemolytic anemia (patient information)|Secondary immune hemolytic anemia]]
*[[Immune hemolytic anemia (patient information)|Secondary immune hemolytic anemia]]<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue=  | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656  }} </ref>
*[[Immune hemolytic anemia (patient information)|Idiopathic autoimmune hemolytic anemia]]
*[[Immune hemolytic anemia (patient information)|Idiopathic autoimmune hemolytic anemia]]
*[[Non immune hemolytic anemia (patient information)|Non-immune hemolytic anemia]] caused by chemicals or toxins
*[[Non immune hemolytic anemia (patient information)|Non-immune hemolytic anemia]] caused by [[chemicals]] or [[toxins]]
*Microangiopathic hemolytic anemia (MAHA)
*[[Microangiopathic hemolytic anemia|Microangiopathic hemolytic anemia (MAHA)]]
*[[Sickle-cell disease (patient information)|Sickle-cell anemia]]
*[[Sickle-cell disease (patient information)|Sickle-cell anemia]]
*Hemoglobin SC disease (similar in symptoms to [[Sickle-cell disease (patient information)|sickle-cell anemia]])
*[[Hemoglobin SC disease]] (similar in symptoms to [[Sickle-cell disease (patient information)|sickle-cell anemia]])
*[[Thalassemia (patient information)|Thalassemia]]
*[[Thalassemia (patient information)|Thalassemia]]
*Hemolytic anemia due to [[Glucose-6-phosphate dehydrogenase deficiency (patient information)|G6PD deficiency]]
*Hemolytic anemia due to [[Glucose-6-phosphate dehydrogenase deficiency (patient information)|G6PD deficiency]]
*[[Paroxysmal nocturnal hemoglobinuria (patient information)|Paroxysmal nocturnal hemoglobinuria]] (PNH)
*[[Paroxysmal nocturnal hemoglobinuria (patient information)|Paroxysmal nocturnal hemoglobinuria]] (PNH)
*[[Hereditary elliptocytosis (patient information)|Hereditary elliptocytosis]]
*[[Hereditary elliptocytosis (patient information)|Hereditary elliptocytosis]]
*Hereditary [[ovalocytosis]]
*[[Hereditary]] [[ovalocytosis]]
*[[Hereditary spherocytosis (patient information)|Hereditary spherocytosis]]
*[[Hereditary spherocytosis (patient information)|Hereditary spherocytosis]]
*[[Malaria (patient information)|Malaria]]
*[[Malaria (patient information)|Malaria]]<ref name="pmid25898007">{{cite journal| author=Jauréguiberry S, Thellier M, Ndour PA, Ader F, Roussel C, Sonneville R et al.| title=Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013. | journal=Emerg Infect Dis | year= 2015 | volume= 21 | issue= 5 | pages= 804-12 | pmid=25898007 | doi=10.3201/eid2105.141171 | pmc=4412216 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25898007  }} </ref>
*Transfusion of blood from a donor with a different blood type
*[[Blood transfusion|Transfusion of blood]] from a donor with a [[Blood type|different blood type]]


'''Hemolytic anemias can be either genetic or acquired.'''
'''Hemolytic anemias can be either genetic or acquired.'''
Line 26: Line 31:
===Genetic===
===Genetic===
*Genetic conditions of RBC membrane
*Genetic conditions of RBC membrane
**[[Hereditary spherocytosis]]
**[[Hereditary spherocytosis]]<ref name="pmid21193012">{{cite journal| author=Hughes MR, Anderson N, Maltby S, Wong J, Berberovic Z, Birkenmeier CS et al.| title=A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis. | journal=Exp Hematol | year= 2011 | volume= 39 | issue= 3 | pages= 305-20, 320.e1-2 | pmid=21193012 | doi=10.1016/j.exphem.2010.12.009 | pmc=3404605 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21193012  }} </ref>
**[[Hereditary elliptocytosis]]
**[[Hereditary elliptocytosis]]<ref name="pmid6894932">{{cite journal| author=Tchernia G, Mohandas N, Shohet SB| title=Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary elliptocytosis. Implications for erythrocyte membrane stability. | journal=J Clin Invest | year= 1981 | volume= 68 | issue= 2 | pages= 454-60 | pmid=6894932 | doi= | pmc=370818 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6894932  }} </ref>
*Genetic conditions of RBC metabolism ([[enzyme]] defects)
*Genetic conditions of RBC metabolism ([[enzyme]] defects)
**[[Glucose-6-phosphate dehydrogenase deficiency]] (G6PD or favism)
**[[Glucose-6-phosphate dehydrogenase deficiency]] (G6PD or [[favism]])
**[[Pyruvate kinase deficiency]]
**[[Pyruvate kinase deficiency]]
*Genetic conditions of hemoglobin
*Genetic conditions of hemoglobin
**[[Sickle cell anemia]]  
**[[Sickle cell anemia]]  
**[[Thalassemia]]
**[[Thalassemia]]
===Acquired===
===Acquired===


Acquired hemolytic anemia can be further divided into immune and non-immune mediated.
Acquired hemolytic anemia can be further divided into [[immune]] and non-immune mediated.


'''Immune mediated hemolytic anaemia''' (direct [[Coombs test]] is positive)
'''Immune-mediated hemolytic anemia''' (direct [[Coombs test]] is positive)
*[[Autoimmune hemolytic anemia]]
*[[Autoimmune hemolytic anemia]]<ref name="pmid26696800">{{cite journal| author=Packman CH| title=The Clinical Pictures of Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 317-24 | pmid=26696800 | doi=10.1159/000440656 | pmc=4678314 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696800  }} </ref>
**[[Warm antibody autoimmune hemolytic anemia]]
**[[Warm antibody autoimmune hemolytic anemia]]
***[[Idiopathic]]
***[[Idiopathic]]
***[[Systemic lupus erythematosus]] (SLE)
***[[Systemic lupus erythematosus]] (SLE)<ref name="pmid25949934">{{cite journal| author=Fujii J, Kurahashi T, Konno T, Homma T, Iuchi Y| title=Oxidative stress as a potential causal factor for autoimmune hemolytic anemia and systemic lupus erythematosus. | journal=World J Nephrol | year= 2015 | volume= 4 | issue= 2 | pages= 213-22 | pmid=25949934 | doi=10.5527/wjn.v4.i2.213 | pmc=4419130 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25949934  }} </ref>
***[[Evans' syndrome]] (antiplatelet antibodies and haemolytic antibodies)
***[[Evans' syndrome]] (antiplatelet antibodies and haemolytic antibodies)
**[[Cold agglutinin disease|Cold antibody autoimmune hemolytic anemia]]
**[[Cold agglutinin disease|Cold antibody autoimmune hemolytic anemia]]
***[[Idiopathic cold hemagglutinin syndrome]]
***[[Idiopathic cold hemagglutinin syndrome]]
***[[Infectious mononucleosis]] and mycoplasma ( atypical) pneumonia
***[[Infectious mononucleosis]] and [[Mycoplasma pneumonia|mycoplasma (atypical) pneumonia]]
***[[Paroxysmal cold hemoglobinuria]] (rare)
***[[Paroxysmal cold hemoglobinuria]] (rare)<ref name="pmid26696800">{{cite journal| author=Packman CH| title=The Clinical Pictures of Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 317-24 | pmid=26696800 | doi=10.1159/000440656 | pmc=4678314 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696800  }} </ref>
*[[Alloimmune]] hemolytic anemia
*[[Alloimmune]] hemolytic anemia
**[[Haemolytic disease of the newborn]] (HDN)
**[[Haemolytic disease of the newborn]] (HDN)
Line 56: Line 62:
***[[Hemolytic disease of the newborn (anti-RhE)|Rhesus E hemolytic disease of the newborn]]
***[[Hemolytic disease of the newborn (anti-RhE)|Rhesus E hemolytic disease of the newborn]]
***Other [[Blood type|blood group]] incompatibility (RhC, Rhe, [[Kidd antigen system|Kidd]], [[Duffy antigen|Duffy]], MN, P and others)
***Other [[Blood type|blood group]] incompatibility (RhC, Rhe, [[Kidd antigen system|Kidd]], [[Duffy antigen|Duffy]], MN, P and others)
**Alloimmune hemolytic [[Blood transfusion#Complications|blood transfusion]] reactions (ie from a non-compatible [[blood type]])
**[[Alloimmune]] hemolytic [[Blood transfusion#Complications|blood transfusion]] reactions (ie from a non-compatible [[blood type]])
*Drug induced immune mediated hemolytic anemia
*Drug induced immune mediated hemolytic anemia
**[[Penicillin]] (high dose)
**[[Penicillin]] (high dose)
**[[Methyldopa]]
**[[Methyldopa]]


'''Non-immune mediated hemolytic anemia''' (direct [[Coombs test]] is negative)
'''Non-immune mediated hemolytic anemia''' (direct [[Coombs test]] is negative)<ref name="pmid26696800">{{cite journal| author=Packman CH| title=The Clinical Pictures of Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 317-24 | pmid=26696800 | doi=10.1159/000440656 | pmc=4678314 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696800  }} </ref>
*[[Medication|Drugs]] (i.e., some drugs and other ingested substances lead to hemolysis by direct action on RBCs)
*[[Medication|Drugs]] (i.e., some [[drugs]] and other ingested substances lead to [[hemolysis]] by direct action on [[RBCs]])
*[[Toxin]]s (e.g., snake venom)
*[[Toxin]]s (e.g., [[Snake venoms|snake venom]])
*Trauma
*[[Trauma]]
**Mechanical ([[heart valve]]s, extensive vascular surgery, microvascular disease)
**Mechanical ([[heart valve]]s, extensive [[vascular surgery]], and [[microvascular disease]])
*[[Microangiopathic hemolytic anemia]] (a specific subtype with causes such as TTP, HUS, DIC and HELLP syndrome)
*[[Microangiopathic hemolytic anemia]] (a specific subtype with causes such as [[Thrombotic thrombocytopenic purpura|TTP]], [[Hemolytic-uremic syndrome|HUS]], [[DIC]], and [[HELLP syndrome]])
*Infections
*[[Infections]]
**[[Malaria]]
**[[Malaria]]
**[[Babesiosis]]
**[[Babesiosis]]
Line 77: Line 83:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Hematology]]
{{WS}}
{{WH}}

Latest revision as of 17:17, 30 October 2017

Hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI Scan

Echocardiography or Ultrasound

Imaging Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic anemia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic anemia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic anemia classification

CDC on Hemolytic anemia classification

Hemolytic anemia classification in the news

Blogs on Hemolytic anemia classification

Directions to Hospitals Treating Hemolytic anemia

Risk calculators and risk factors for Hemolytic anemia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Shyam Patel [2]

Overview

Hemolytic anemia can be divided into intravascular and extravascular based on whether the destruction of RBCs occurs in the vessels or outside the vessels, usually in spleen and liver. Extravascular hemolytic anemia is more common than intravascular hemolytic anemia. There are many types of hemolytic anemias and the general classification of hemolytic anemia is either acquired or inherited (genetic). Genetic conditions include red blood cell membrane or enzyme defects that predispose the red blood cells to hemolysis.

Classification

Location of Hemolysis

Types of Hemolytic Anemias

Hemolytic anemias can be either genetic or acquired.

Genetic

Acquired

Acquired hemolytic anemia can be further divided into immune and non-immune mediated.

Immune-mediated hemolytic anemia (direct Coombs test is positive)

Non-immune mediated hemolytic anemia (direct Coombs test is negative)[5]

References

  1. Berentsen S, Sundic T (2015). "Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy". Biomed Res Int. 2015: 363278. doi:10.1155/2015/363278. PMC 4326213. PMID 25705656.
  2. Jauréguiberry S, Thellier M, Ndour PA, Ader F, Roussel C, Sonneville R; et al. (2015). "Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013". Emerg Infect Dis. 21 (5): 804–12. doi:10.3201/eid2105.141171. PMC 4412216. PMID 25898007.
  3. Hughes MR, Anderson N, Maltby S, Wong J, Berberovic Z, Birkenmeier CS; et al. (2011). "A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis". Exp Hematol. 39 (3): 305–20, 320.e1–2. doi:10.1016/j.exphem.2010.12.009. PMC 3404605. PMID 21193012.
  4. Tchernia G, Mohandas N, Shohet SB (1981). "Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary elliptocytosis. Implications for erythrocyte membrane stability". J Clin Invest. 68 (2): 454–60. PMC 370818. PMID 6894932.
  5. 5.0 5.1 5.2 Packman CH (2015). "The Clinical Pictures of Autoimmune Hemolytic Anemia". Transfus Med Hemother. 42 (5): 317–24. doi:10.1159/000440656. PMC 4678314. PMID 26696800.
  6. Fujii J, Kurahashi T, Konno T, Homma T, Iuchi Y (2015). "Oxidative stress as a potential causal factor for autoimmune hemolytic anemia and systemic lupus erythematosus". World J Nephrol. 4 (2): 213–22. doi:10.5527/wjn.v4.i2.213. PMC 4419130. PMID 25949934.

Template:WS Template:WH